Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Mind Medicine

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Recipient: MindShift Compounds

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 11, 2021

            Details:

            The partnership on these initial targets will expand MindMed’s current, well-established clinical pipeline with additional backup and expansion compounds with similar and potentially improved therapeutic properties.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSD

            Therapeutic Area: Psychiatry/Psychology Product Name: LSD

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Canaccord Genuity Corp

            Deal Size: $62.8 million Upfront Cash: Undisclosed

            Deal Type: Financing December 21, 2020

            Details:

            Net proceeds of the Offering will be used in the company's digital medicine division, its development of a non-hallucinogenic version of the psychedelic ibogaine to address the opioid crisis, and its LSD micro-dosing trials for adult ADHD and for general working capital.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSD

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            The company has now reached an agreement with University Hospital Basel Liechti Lab to conduct an interim analysis anticipated in Q1 2021 for its Phase 2a clinical trial of LSD assisted therapy for anxiety disorders currently ongoing in Switzerland.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSD

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            Experiential dose of 200 ug LSD was shown to induce greater ego dissolution than a lesser 100 ug dose. The completed Phase 1 study will help MindMed in dose-finding and planning the future Phase 2 clinical trials of LSD in patients with anxiety disorders and other conditions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Recipient: Liechti Lab

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 24, 2020

            Details:

            As part of this exclusive license agreement MindMed will retain an exclusive license to all IP and any patents generated from data or findings in the study and related work on psilocybin, such as pharmacokinetic data and information on the metabolism.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Methamphetamine Hydrochloride,LSD

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            Details:

            The MDMA-LSD trial, the first-ever to combine both drugs, is scheduled to start in the fourth quarter in Basel, Switzerland. Combined MDMA-LSD treatments have the potential to create next-generation psychedelic-assisted therapy paradigms.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSD

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Liechti Lab

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 08, 2020

            Details:

            Mind Medicine is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel’s Liechti Lab.